Theravance Biopharma (TBPH) Gains from Investment Securities (2013 - 2026)
Theravance Biopharma (TBPH) reported Gains from Investment Securities of $2393.0 for Q1 2026, down 99.87% year-over-year from $1.9 million in Q1 2025, and up 100.14% quarter-over-quarter from -$1.7 million in Q4 2025.
Theravance Biopharma (TBPH) Gains from Investment Securities (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Gains from Investment Securities data on file, last reported at $2393.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $2393.0, down 99.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $2393.0 (down 99.87% YoY), and the FY2025 annual result was $1.9 million, up 1.61% from the prior year.
- Gains from Investment Securities improved to $2393.0 in Q1 2026 per TBPH's latest filing, from -$1.7 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $2.3 million in Q1 2024 and troughed at -$1.7 million in Q4 2025.
- A 5-year average of $643350.1 and a median of $169806.0 in 2025 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities surged 5180.0% in 2024, then plunged 420.45% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $993000.0 in 2022, then plunged by 98.99% to $10000.0 in 2023, then surged by 5180.0% to $528000.0 in 2024, then sank by 420.45% to -$1.7 million in 2025, then soared by 100.14% to $2393.0 in 2026.
- Business Quant data shows TBPH's Gains from Investment Securities at $2393.0 in Q1 2026, -$1.7 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Theravance Biopharma | 846.10 Mn | 451.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,393.00 |
| Mar 31, 2026 | 2,393.00 |
| Dec 31, 2025 | -1.69 Mn |
| Dec 31, 2025 | -1.69 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 169,806.00 |
| Jun 30, 2025 | 169,806.00 |
| Mar 31, 2025 | 1.90 Mn |
| Mar 31, 2025 | 1.90 Mn |
| Dec 31, 2024 | 528,000.00 |
| Dec 31, 2024 | 528,000.00 |
| Sep 30, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Mar 31, 2024 | 2.30 Mn |
| Mar 31, 2024 | 2.30 Mn |
| Dec 31, 2023 | 10,000.00 |
| Dec 31, 2023 | 10,000.00 |